LR Kelland - Concepedia

Author

LR Kelland

Institute of Cancer Research

Also Known As

Kelland, L., L Kelland, L R Kelland, L. Kelland, L. R. KELLAND, L. R. Kelland, L.R. Kelland, LR KELLAND, LR Kelland

Publications

Citations

H-Index

Concepts

All Affiliations

Institute of Cancer Research

About

LR Kelland is an author at Institute of Cancer Research specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	20	1.1K
2	Cell Biology	10	10	708
3	Biochemistry	5	5	172
4	Natural Sciences	4	4	140
5	Health Sciences	1	1	33

LR Kelland

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
DT-Diaphorase Expression and Tumor Cell Sensitivity to 17-Allylamino,17-demethoxygeldanamycin, an Inhibitor of Heat Shock Protein 90 LR Kelland, Swee Y. Sharp, Paul Rogers, JNCI Journal of the National Cancer Institute	1999	350
Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. Nicholas P. Farrell, LR Kelland, John D. Roberts, PubMed Chemoprevention StrategyTrans ComplexesTumor BiologyMedicinal ChemistryOncology	1992	175
Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes Prakash Mistry, LR Kelland, G Abel British Journal of Cancer Novel PlatinumMedicinePharmacologyAmmine/amine ComplexesDrug Accumulation	1992	168
Induction of apoptosis by a novel copper-based anticancer compound, Casiopeina II, in L1210 murine leukaemia and CH1 human ovarian carcinoma cells Andrea De Vizcaya‐Ruíz, Adolfo Rivero‐Müller, George E.N. Kass, Toxicology in Vitro L1210 Murine LeukaemiaMedicineApoptosisPharmacologyCell Death	2000	133
In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin Mellish Kj, LR Kelland, KR Harrap British Journal of Cancer Cervical CancerMedicinePharmacologyAnti-cancer AgentCancer Treatment	1993	113
BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma Philip Beale, Paul Rogers, Frances Boxall, British Journal of Cancer	2000	109
Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo Dashuang Shi, LR Kelland, A. Wilson, British Journal of Cancer MedicinePharmacologyGynecologyAnti-cancer AgentOncology	1998	68
Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Swee Y. Sharp, Paul Rogers, LR Kelland PubMed Chemoprevention StrategyMolecular BiologyCancer BiologyTumor BiologyOvarian Cancer	1995	53
Telomerase as an anti-cancer target: current status and future prospects. Stephen Neidle, LR Kelland PubMed Tumor BiologyShort TelomeresOncogenic AgentGradual Telomere ErosionTelomeric Dna	1999	42
Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin CF O'Neill, Beate Köberle, John R. Masters, British Journal of Cancer Oncogenic AgentGene-specific RepairPt/dna LesionsMedicinePathology	1999	39

Page 1